[1]
NOON L. Prophylactic inoculation against hay fever (historical document). Annals of allergy. 1955 Nov-Dec:13(6):713-6; passim
[PubMed PMID: 13268980]
[2]
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. Allergen immunotherapy: a practice parameter third update. The Journal of allergy and clinical immunology. 2011 Jan:127(1 Suppl):S1-55. doi: 10.1016/j.jaci.2010.09.034. Epub 2010 Dec 3
[PubMed PMID: 21122901]
[3]
Tanno LK, Calderon MA, Papadopoulos NG, Sanchez-Borges M, Rosenwasser LJ, Bousquet J, Pawankar R, Sisul JC, Cepeda AM, Li J, Muraro A, Fineman S, Sublett JL, Katelaris CH, Chang YS, Moon HB, Casale T, Demoly P, Joint Allergy Academies. Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11. The journal of allergy and clinical immunology. In practice. 2016 Jul-Aug:4(4):643-9. doi: 10.1016/j.jaip.2015.12.022. Epub 2016 Mar 8
[PubMed PMID: 26969269]
[4]
Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, Ryan D, Agache I, Ansotegui IJ, Arasi S, Du Toit G, Fernandez-Rivas M, Geerth van Wijk R, Jutel M, Kleine-Tebbe J, Lau S, Matricardi PM, Pajno GB, Papadopoulos NG, Penagos M, Santos AF, Sturm GJ, Timmermans F, van Ree R, Varga EM, Wahn U, Kristiansen M, Dhami S, Sheikh A, Muraro A. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2017 Dec:28(8):728-745. doi: 10.1111/pai.12807. Epub 2017 Oct 27
[PubMed PMID: 28902467]
[5]
Di Lorenzo G, Leto-Barone MS, La Piana S, Plaia A, Di Bona D. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. International forum of allergy & rhinology. 2017 Jul:7(7):660-669. doi: 10.1002/alr.21946. Epub 2017 May 23
[PubMed PMID: 28544523]
Level 1 (high-level) evidence
[6]
Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, Muraro A, Roberts G, Akdis CA, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci Ö, Mosges R, Palomares O, Pfaar O, Smolinska S, Sokolowska M, Asaria M, Netuveli G, Zaman H, Akhlaq A, Sheikh A. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017 Dec:72(12):1825-1848. doi: 10.1111/all.13208. Epub 2017 Jul 6
[PubMed PMID: 28543086]
Level 1 (high-level) evidence
[7]
Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, Larenas-Linnemann D, Calderón MA, Penagos M, Du Toit G, Ansotegui IJ, Kleine-Tebbe J, Lau S, Matricardi PM, Pajno G, Papadopoulos NG, Pfaar O, Ryan D, Santos AF, Timmermanns F, Wahn U, Sheikh A. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2017 Feb:28(1):18-29. doi: 10.1111/pai.12661. Epub 2016 Dec 12
[PubMed PMID: 27653623]
Level 1 (high-level) evidence
[8]
Klimek L, Pfaar O, Bousquet J, Senti G, Kündig T. Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert review of clinical immunology. 2017 Sep:13(9):897-906. doi: 10.1080/1744666X.2017.1333423. Epub 2017 Jun 15
[PubMed PMID: 28532268]
[9]
Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy. 2011 Jun:66(6):725-32. doi: 10.1111/j.1398-9995.2011.02589.x. Epub 2011 Apr 6
[PubMed PMID: 21466562]
[10]
James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008 Jul:38(7):1074-88. doi: 10.1111/j.1365-2222.2008.02976.x. Epub
[PubMed PMID: 18691292]
[11]
van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, Rückert B, Akdis CA, Akdis M. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. The Journal of allergy and clinical immunology. 2013 Apr:131(4):1204-12. doi: 10.1016/j.jaci.2013.01.014. Epub 2013 Feb 26
[PubMed PMID: 23453135]
[12]
Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. The Journal of allergy and clinical immunology. 2017 Dec:140(6):1485-1498. doi: 10.1016/j.jaci.2017.10.010. Epub
[PubMed PMID: 29221580]
[13]
Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet MR, Zaph C, Takei F, McNagny KM. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. The Journal of allergy and clinical immunology. 2014 Apr:133(4):1142-8. doi: 10.1016/j.jaci.2014.02.033. Epub
[PubMed PMID: 24679471]
[14]
Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, Ellis A, Golden DB, Greenberger P, Kemp S, Khan D, Ledford D, Lieberman J, Metcalfe D, Nowak-Wegrzyn A, Sicherer S, Wallace D, Blessing-Moore J, Lang D, Portnoy JM, Schuller D, Spector S, Tilles SA. Anaphylaxis--a practice parameter update 2015. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2015 Nov:115(5):341-84. doi: 10.1016/j.anai.2015.07.019. Epub
[PubMed PMID: 26505932]
[15]
Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA, Antolín-Amérigo D, Cichocka-Jarosz E, Gawlik R, Jakob T, Kosnik M, Lange J, Mingomataj E, Mitsias DI, Ollert M, Oude Elberink JNG, Pfaar O, Pitsios C, Pravettoni V, Ruëff F, Sin BA, Agache I, Angier E, Arasi S, Calderón MA, Fernandez-Rivas M, Halken S, Jutel M, Lau S, Pajno GB, van Ree R, Ryan D, Spranger O, van Wijk RG, Dhami S, Zaman H, Sheikh A, Muraro A. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018 Apr:73(4):744-764. doi: 10.1111/all.13262. Epub 2017 Dec 5
[PubMed PMID: 28748641]
[16]
Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. The Journal of allergy and clinical immunology. 1993 Jul:92(1 Pt 1):6-15
[PubMed PMID: 8335856]
Level 3 (low-level) evidence
[17]
Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. The Journal of allergy and clinical immunology. 2004 Jun:113(6):1129-36
[PubMed PMID: 15208595]
Level 3 (low-level) evidence
[18]
Bernstein DI, Bardelas JA Jr, Svanholm Fogh B, Kaur A, Li Z, Nolte H. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Postgraduate medicine. 2017 Aug:129(6):590-597. doi: 10.1080/00325481.2017.1302306. Epub 2017 Mar 22
[PubMed PMID: 28326906]
[19]
Nolte H, Casale TB, Lockey RF, Fogh BS, Kaur A, Lu S, Nelson HS. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. The journal of allergy and clinical immunology. In practice. 2017 Jan-Feb:5(1):84-89.e3. doi: 10.1016/j.jaip.2016.08.017. Epub 2016 Nov 9
[PubMed PMID: 27838323]
[20]
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C, (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug:62(8):943-8
[PubMed PMID: 17620073]
[21]
Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, Klink R, GAP investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. The Journal of allergy and clinical immunology. 2018 Feb:141(2):529-538.e13. doi: 10.1016/j.jaci.2017.06.014. Epub 2017 Jul 6
[PubMed PMID: 28689794]
[22]
Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. American journal of respiratory and critical care medicine. 2000 Dec:162(6):2048-52
[PubMed PMID: 11112112]
[23]
Cox L. The role of allergen immunotherapy in the management of allergic rhinitis. American journal of rhinology & allergy. 2016 Jan-Feb:30(1):48-53. doi: 10.2500/ajra.2016.30.4253. Epub
[PubMed PMID: 26867530]
[24]
Nelson HS, Makatsori M, Calderon MA. Subcutaneous Immunotherapy and Sublingual Immunotherapy: Comparative Efficacy, Current and Potential Indications, and Warnings--United States Versus Europe. Immunology and allergy clinics of North America. 2016 Feb:36(1):13-24. doi: 10.1016/j.iac.2015.08.005. Epub
[PubMed PMID: 26617224]
Level 2 (mid-level) evidence
[25]
Feng B, Wu J, Chen B, Xiang H, Chen R, Li B, Chen S. Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: A meta-analysis of randomized controlled trials. American journal of rhinology & allergy. 2017 Jan 1:31(1):27-35. doi: 10.2500/ajra.2017.31.4382. Epub
[PubMed PMID: 28234149]
Level 1 (high-level) evidence
[26]
Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, Durham SR, Jacobsen L, Malling HJ, Mösges R, Papadopoulos NG, Rak S, Rodriguez del Rio P, Valovirta E, Wahn U, Calderon MA, European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014 Jul:69(7):854-67. doi: 10.1111/all.12383. Epub 2014 Apr 25
[PubMed PMID: 24761804]
Level 2 (mid-level) evidence
[27]
Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, Agarwal A, Netuveli G, Roberts G, Pfaar O, Muraro A, Ansotegui IJ, Calderon M, Cingi C, Durham S, van Wijk RG, Halken S, Hamelmann E, Hellings P, Jacobsen L, Knol E, Larenas-Linnemann D, Lin S, Maggina P, Mösges R, Oude Elberink H, Pajno G, Panwankar R, Pastorello E, Penagos M, Pitsios C, Rotiroti G, Timmermans F, Tsilochristou O, Varga EM, Schmidt-Weber C, Wilkinson J, Williams A, Worm M, Zhang L, Sheikh A. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017 Nov:72(11):1597-1631. doi: 10.1111/all.13201. Epub 2017 Jul 14
[PubMed PMID: 28493631]
Level 1 (high-level) evidence
[28]
Nelson HS. Allergen immunotherapy now and in the future. Allergy and asthma proceedings. 2016 Jul:37(4):268-72. doi: 10.2500/aap.2016.37.3966. Epub
[PubMed PMID: 27401313]
[29]
Reisacher WR, Schwanke T. New advances in allergy immunotherapy. Current opinion in otolaryngology & head and neck surgery. 2016 Jun:24(3):231-7. doi: 10.1097/MOO.0000000000000255. Epub
[PubMed PMID: 26926847]
Level 3 (low-level) evidence
[30]
Lim CE, Sison CP, Ponda P. Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy. The journal of allergy and clinical immunology. In practice. 2017 Sep-Oct:5(5):1241-1247.e2. doi: 10.1016/j.jaip.2017.01.014. Epub 2017 Mar 21
[PubMed PMID: 28341172]
[31]
Larenas-Linnemann DE, Hauswirth DW, Calabria CW, Sher LD, Rank MA. American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. Allergy and asthma proceedings. 2016 Sep:37(5):112-22. doi: 10.2500/aap.2016.37.3981. Epub
[PubMed PMID: 27657518]
[32]
Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, Brough HA, Santos AF, Harris KM, Radulovic S, Basting M, Turcanu V, Plaut M, Lack G, Immune Tolerance Network LEAP-On Study Team. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. The New England journal of medicine. 2016 Apr 14:374(15):1435-43. doi: 10.1056/NEJMoa1514209. Epub 2016 Mar 4
[PubMed PMID: 26942922]